{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:25:22Z","timestamp":1780514722043,"version":"3.54.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT), is a rare subset of primary cutaneous lymphoma known for its aggressive behavior, poor prognosis, and limited treatment options, particularly in the relapsed or refractory setting. We report a case of a patient diagnosed with PCDLBCL-LT who achieved a clinically significant response and sustained remission for seven months with acalabrutinib, a covalent inhibitor of Bruton\u2019s tyrosine kinase (BTK), before disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>An 88-year-old woman presented with a rapidly enlarging ulcerated lesion on the left lower leg. Histopathological and immunohistochemical analyses confirmed the diagnosis of PCDLBCL-LT. She was treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemoimmunotherapy, followed by external beam radiation therapy (RT). These interventions resulted in only a partial response, and the disease progressed within several months. The patient was receiving direct oral anticoagulant (DOAC) therapy for left lower limb deep vein thrombosis, and she also had a history of hypertension. Considering the increased risk of major bleeding associated with DOAC use and the elevated risk of cardiovascular adverse events previously reported with ibrutinib, an alternative BTK inhibitor was considered. Accordingly, she was initiated on acalabrutinib at a dose of 100 mg orally twice daily. The patient exhibited a rapid and robust clinical response, with complete resolution of cutaneous lesions and sustained remission lasting seven months. Ultimately, the disease progressed, and given her advanced age and overall poor performance status, she was transitioned to hospice care. She subsequently died 14 months after initiating acalabrutinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This report documents the first known case of successful treatment of relapsed\/refractory PCDLBCL-LT with acalabrutinib. Despite advanced age and poor performance status, the patient experienced rapid symptom resolution and durable remission without treatment-related adverse events. These findings suggest that BTK inhibitors may represent a promising therapeutic approach for PCDLBCL-LT, either as monotherapy or in combination with anti-CD20 antibodies. Further investigation into novel targeted therapies is urgently needed for this rare and aggressive lymphoma subtype.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1771103","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T05:22:41Z","timestamp":1773638561000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Acalabrutinib treatment in relapsed\/refractory primary cutaneous diffuse large B cell lymphoma, leg type. Case report"],"prefix":"10.3389","volume":"16","author":[{"given":"David A.","family":"Martinez-Gamboa","sequence":"first","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic","place":["Phoenix, AZ, United States"]},{"name":"Cancer Research and Cellular Therapies Laboratory, Mayo Clinic","place":["Phoenix, AZ, United States"]},{"name":"Department of Internal Medicine, Mayo Clinic","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio F.","family":"Beas","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic","place":["Phoenix, AZ, United States"]},{"name":"Cancer Research and Cellular Therapies Laboratory, Mayo Clinic","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eider","family":"Moreno-Cortes","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic","place":["Phoenix, AZ, United States"]},{"name":"Cancer Research and Cellular Therapies Laboratory, Mayo Clinic","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah A.","family":"Swanson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mayo Clinic","place":["Phoenix, AZ, United States"]},{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic","place":["Scottsdale, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron R.","family":"Mangold","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic","place":["Phoenix, AZ, United States"]},{"name":"Department of Dermatology, Mayo Clinic","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Vargas","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic","place":["Phoenix, AZ, United States"]},{"name":"Cancer Research and Cellular Therapies Laboratory, Mayo Clinic","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Januario E.","family":"Castro","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic","place":["Phoenix, AZ, United States"]},{"name":"Cancer Research and Cellular Therapies Laboratory, Mayo Clinic","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071202","article-title":"Unveiling primary cutaneous B-cell lymphomas: new insights into diagnosis and treatment strategies","volume":"17","author":"Barbati","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/j.seminhematol.2015.01.006","article-title":"The histological classification of diffuse large B-cell lymphomas","volume":"52","author":"Xie","year":"2015","journal-title":"Semin Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2012-0195-RA","article-title":"Primary cutaneous diffuse large B-cell lymphoma, leg type: diagnostic considerations","volume":"136","author":"Hristov","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.mpdhp.2024.05.002","article-title":"New insights and advances in defining primary cutaneous B-cell lymphomas and cutaneous B-cell rich lymphoid proliferations","author":"Prieto-Torres","year":"2024","journal-title":"Diagn Histopathology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.det.2022.07.014","article-title":"A practical review of the presentation, diagnosis, and management of cutaneous B-cell lymphomas","volume":"41","author":"Goyal","year":"2023","journal-title":"Dermatol Clin"},{"key":"B10","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2023.12.019","article-title":"Response to Bruton\u2019s tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy","volume":"42","author":"Phelan","year":"2024","journal-title":"Cancer Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","article-title":"BTK inhibitors in the treatment of hematological Malignancies and inflammatory diseases: mechanisms and clinical studies","volume":"15","author":"Alu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.7452","article-title":"Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France","volume":"150","author":"Grange","year":"2014","journal-title":"JAMA Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep15030053","article-title":"CD5+ Primary cutaneous diffuse large B-cell lymphoma, leg type, presenting as an asymptomatic nodule","volume":"15","author":"Xiao","year":"2023","journal-title":"Hematol Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S0190-9622(94)70135-0","article-title":"Primary cutaneous B-cell lymphomas in Japan. A report of three cases and a comparison of Japanese and white patients","volume":"31","author":"Tanaka","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1159\/000058320","article-title":"De novo CD5-positive diffuse large B cell lymphoma solely presenting as multiple subcutaneous nodules","volume":"107","author":"Takahashi","year":"2002","journal-title":"Acta Haematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00414.x","article-title":"Effective in vivo purging with rituximab and autologous peripheral blood stem cell transplantation in a woman with CD5 positive primary cutaneous diffuse large B-cell lymphoma","volume":"74","author":"Goto","year":"2005","journal-title":"Eur J Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500051208","article-title":"De novo CD5-positive diffuse large B-cell lymphoma of the skin arising in chronic limb lymphedema","volume":"46","author":"Dargent","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000002077","article-title":"A case of CD5-positive primary cutaneous diffuse large B-cell lymphoma, leg type secondary to chronic lymphedema","volume":"44","author":"Sun","year":"2022","journal-title":"Am J Dermatopathol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.9.1144","article-title":"Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases","volume":"143","author":"Grange","year":"2007","journal-title":"Arch Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.semdp.2016.11.006","article-title":"Primary cutaneous B-cell lymphomas with large cell predominance-primary cutaneous follicle center lymphoma, diffuse large B-cell lymphoma, leg type and intravascular large B-cell lymphoma","volume":"34","author":"Hope","year":"2017","journal-title":"Semin Diagn Pathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.821","article-title":"High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type","volume":"150","author":"Pham-Ledard","year":"2014","journal-title":"JAMA Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2919","article-title":"Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"39","author":"Kraft","year":"2021","journal-title":"Hematol Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08239.x","article-title":"The applicability and prognostic value of the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and S\u00e9zary syndrome: results on a large cohort of primary cutaneous B-cell lymphomas and comparison with the system used by the Dutch Cutaneous Lymphoma Group","volume":"157","author":"Senff","year":"2007","journal-title":"Br J Dermatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s40257-022-00704-0","article-title":"Update in diagnosis and management of primary cutaneous B-cell lymphomas","volume":"23","author":"Krenitsky","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01163","article-title":"Innovative therapeutic approaches in primary cutaneous B cell lymphoma","volume":"10","author":"Lang","year":"2020","journal-title":"Front Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1159\/000534784","article-title":"Prolonged complete response with lenalidomide in a relapsed diffuse large B-cell lymphoma, leg-type: A case report","volume":"69","author":"Zoli","year":"2024","journal-title":"Chemotherapy"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28052400","article-title":"Bruton\u2019s tyrosine kinase inhibitors (BTKIs): review of preclinical studies and evaluation of clinical trials","volume":"28","author":"Rozkiewicz","year":"2023","journal-title":"Molecules"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17886","article-title":"Rituximab, lenalidomide, and ibrutinib in relapsed\/refractory primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"196","author":"Moore","year":"2022","journal-title":"Br J Haematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19061758","article-title":"Molecular mechanisms of disease progression in primary cutaneous diffuse large B-cell lymphoma, leg type during ibrutinib therapy","volume":"19","author":"Fox","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"6067","DOI":"10.4081\/rt.2015.6067","article-title":"Excellent outcome of immunomodulation or bruton\u2019s tyrosine kinase inhibition in highly refractory primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"7","author":"Gupta","year":"2015","journal-title":"Rare Tumors"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03787-8","article-title":"Addictive response of primary cutaneous diffuse large B cell lymphoma leg type to low-dose ibrutinib","volume":"98","author":"Pang","year":"2019","journal-title":"Ann Hematol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e8651","DOI":"10.7759\/cureus.8651","article-title":"Primary cutaneous diffuse large B-cell lymphoma, leg type: A case report","volume":"12","author":"Al-Obaidi","year":"2020","journal-title":"Cureus"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.161893","article-title":"Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant","volume":"102","author":"Deng","year":"2017","journal-title":"Haematologica"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1771103\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T05:22:42Z","timestamp":1773638562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1771103\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":35,"alternative-id":["10.3389\/fonc.2026.1771103"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1771103","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"article-number":"1771103"}}